Journal article
CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS
Revista Médica Clínica Las Condes, Vol.28(3), pp.343-351
05/2017
DOI: 10.1016/j.rmclc.2017.05.003
Appears in Diamond Open Access
Abstract
Molecular markers are increasingly being utilized in diagnosing, prognosticating and predicting response to therapy of gliomas. The 4th edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System (CNS) was updated in 2016 and incorporates multiple molecular markers in combination with histology to arrive at an integrated pathological diagnosis1. Newer entities were defined and some were removed based on biological and clinical relevance. Clinical trials have retrospectively incorporated molecular markers and reported patient outcomes based on them, which have showed significant survival differences for specific subtypes of gliomas. Challenges with respect to interobserver variability in diagnosis based on histology alone or availability of minimal diagnostic brain tissue can now be addressed with the use of molecular markers.
Details
- Title: Subtitle
- CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS
- Creators
- Varun Monga - University of IowaKarra Jones - University of IowaSusan Chang - University of California, San Francisco
- Resource Type
- Journal article
- Publication Details
- Revista Médica Clínica Las Condes, Vol.28(3), pp.343-351
- DOI
- 10.1016/j.rmclc.2017.05.003
- ISSN
- 0716-8640
- Publisher
- Elsevier España, S.L.U
- Language
- English
- Date published
- 05/2017
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363293102771
Metrics
6 Record Views